RNA Therapeutics for Improving CAR T-cell Safety and Efficacy

Area of Science:

• Oncology
• Immunotherapy
• RNA Therapeutics

Background:

• Autologous CAR T-cells show promise for hematological cancers but face limitations like toxicity, resistance, and poor solid tumor activity.
• Allogeneic CAR T-cells offer an alternative but encounter challenges related to alloimmunity and host-versus-graft/graft-versus-host disease.
• Current CAR T-cell therapies have significant hurdles impacting their broad clinical application.

Approach:

• This review explores the potential of RNA therapeutics, including small interfering RNAs, microRNAs, and antisense oligonucleotides, to address CAR T-cell limitations.
• RNA therapeutics can modulate gene expression for enhanced CAR T-cell function and safety.
• Investigating combinations of RNA therapeutics with genetic engineering strategies for improved CAR T-cell therapy.

Key Points:

• RNA therapeutics can silence specific transcripts, offering precise control over CAR T-cell behavior.
• Potential to overcome challenges such as antigen escape, toxicity, and immune rejection.
• RNA-based strategies may improve CAR T-cell persistence and activity, particularly against solid tumors.

Conclusions:

• RNA therapeutics represent a promising avenue for overcoming key limitations in current CAR T-cell therapy.
• Harnessing RNA-based approaches can significantly enhance the safety, efficacy, and applicability of both autologous and allogeneic CAR T-cells.
• Future research directions include combining RNA therapeutics with genetic engineering for next-generation CAR T-cell treatments.